Giuseppe Derosa

Summary

Country: Italy

Publications

  1. ncbi Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Clinica Medica IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy
    Am J Hypertens 15:1042-9. 2002
  2. ncbi Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy
    Metabolism 60:421-9. 2011
  3. ncbi Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Piazzale C Golgi 2, Pavia, Italy
    Curr Clin Pharmacol 3:77-84. 2008
  4. ncbi Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro per l Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia, Italy
    Intern Med 47:361-6. 2008
  5. ncbi Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Endothelium 14:175-83. 2007
  6. ncbi Recommendations for the treatment of hypertension in patients with DM: critical evaluation based on clinical trials
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Curr Clin Pharmacol 1:21-33. 2006
  7. ncbi Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Diabetes Nutr Metab 17:222-9. 2004
  8. ncbi Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, P le C Golgi, 2 27100 Pavia, Italy
    Clin Ther 26:1599-607. 2004
  9. ncbi Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, 2 27100 Pavia, Italy
    Diabetes Obes Metab 7:47-55. 2005
  10. ncbi Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    J Cardiovasc Pharmacol 45:599-604. 2005

Detail Information

Publications106 found, 100 shown here

  1. ncbi Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Clinica Medica IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy
    Am J Hypertens 15:1042-9. 2002
    ..The aim of this study is to compare the long-term effect of amlodipine and fosinopril in monotherapy or in combination on urinary albumin excretion (UAE) in hypertensive diabetic patients...
  2. ncbi Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy
    Metabolism 60:421-9. 2011
    ..Sibutramine plus L-carnitine gave a better and faster improvement of all the analyzed parameters compared with sibutramine alone without giving any severe adverse effect...
  3. ncbi Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Piazzale C Golgi 2, Pavia, Italy
    Curr Clin Pharmacol 3:77-84. 2008
    ....
  4. ncbi Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro per l Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia, Italy
    Intern Med 47:361-6. 2008
    ..To compare the effect of delapril/manidipine vs olmesartan/hydrochlorothiazide (HCTZ) combination on insulin sensitivity and plasma fibrinogen in obese hypertensive patients...
  5. ncbi Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Endothelium 14:175-83. 2007
    ..MMPs and TIMP-1 and -2 plasma levels were alterated in nondiabetic and diabetic patients during ACS and after 3 months, which may reflect abnormal extracellular matrix metabolism in diabetes during and after acute event...
  6. ncbi Recommendations for the treatment of hypertension in patients with DM: critical evaluation based on clinical trials
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Curr Clin Pharmacol 1:21-33. 2006
    ....
  7. ncbi Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Diabetes Nutr Metab 17:222-9. 2004
    ....
  8. ncbi Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, P le C Golgi, 2 27100 Pavia, Italy
    Clin Ther 26:1599-607. 2004
    ..Diabetes risk is often complicated by a mixed hyperlipoproteinemia not sufficiently controlled by a single antihyperlipidemic drug; however, there are some concerns about the safety of combined statin and fibrate treatments...
  9. ncbi Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, 2 27100 Pavia, Italy
    Diabetes Obes Metab 7:47-55. 2005
    ....
  10. ncbi Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    J Cardiovasc Pharmacol 45:599-604. 2005
    ..In conclusion, both doxazosin and irbesartan reduced BP during long-term treatment, but not to recommended levels, and doxazosin had the more beneficial effect on glucose metabolism and lipid profile...
  11. ncbi Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Italy
    Pharmacotherapy 25:637-45. 2005
    ....
  12. ncbi A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, P le C Golgi, 2 27100 Pavia, Italy
    Diabetes Res Clin Pract 69:5-13. 2005
    ..To compare the effects of glimepiride plus pioglitazone or plus rosiglitazone in diabetic patients with the metabolic syndrome on coagulation and fibrinolysis parameters...
  13. ncbi Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, P le C Golgi 2, 27100 Pavia, Italy
    Diabetes Res Clin Pract 70:119-25. 2005
    ..It is well known that MMP-9 is an index of the severity and stability of macroangiopathy while our results allow us to postulate that MMP-2 may be a marker of microangiopathy...
  14. ncbi Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Clin Ther 27:1383-91. 2005
    ..Based on a literature search, few direct comparisons of different antihyperglycemic treatments on blood pressure have been reported...
  15. ncbi Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Diabetes Obes Metab 8:197-205. 2006
    ....
  16. ncbi Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Italy
    Hypertens Res 28:917-24. 2005
    ....
  17. ncbi Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    J Cardiovasc Pharmacol 47:508-12. 2006
    ..05) in hypertensive patients after antihypertensive treatment. These results suggest that doxazosin treatment exerts anti-inflammatory effects in addition to its antihypertensive properties in hypertensive patients...
  18. ncbi Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Endothelium 13:227-31. 2006
    ..0001) and for TIMP-1 (p < .0001) in hypertensive patients. Plasma levels and activities of MMP-2, MMP-9, and TIMP-1 are increased in hypertensive patients, which may reflect abnormal ECM metabolism...
  19. ncbi Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Clin Ther 28:679-88. 2006
    ....
  20. ncbi Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    J Int Med Res 34:545-55. 2006
    ....
  21. ncbi Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, doubl
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Clin Ther 26:1228-36. 2004
    ..Angiotensin receptor blockers (ARBs) provide effective blood pressure control. Whereas none of the ARBs appear to affect glucose homeostasis, some ARBs have been associated with a decrease in cholesterolemia...
  22. ncbi Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, Section of Internal Medicine, Vascular and Metabolic Diseases, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, P le C Golgi, Italy
    Obes Res 12:1322-6. 2004
    ..The hypothesis of this study was to assess whether there are differences in the distribution of apo(a) phenotypes between obese patients and healthy controls...
  23. ncbi Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Clin Ther 25:472-84. 2003
    ..Repaglinide and glimepiride are relatively new oral hypoglycemic agents. Few data are available concerning their effects on metabolic parameters other than measures of glycemic control...
  24. ncbi The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Clin Ther 25:1429-39. 2003
    ..A previous study has demonstrated that L-carnitine reduces plasma lipoprotein(a) (Lp[a]) levels in patients with hypercholesterolemia...
  25. ncbi Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    J Int Med Res 33:284-94. 2005
    ....
  26. ncbi Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Clin Ther 25:1107-22. 2003
    ....
  27. ncbi Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Piazzale C Golgi 2, 27100 Pavia, Italy
    Clin Ther 26:744-54. 2004
    ..Glimepiride is approved as monotherapy and in combination with metformin or with insulin, whereas the combination of glimepiride with other antihyperglycemic drugs is under investigation...
  28. ncbi Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Italy
    Hypertens Res 27:457-64. 2004
    ....
  29. ncbi Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Diabetes Nutr Metab 17:143-50. 2004
    ..These reductions may be owing to improved glucose metabolism, but it cannot be excluded that these drugs have a direct effect on additional metabolic parameters...
  30. ncbi A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, IRCCS Policlinico S Matteo, Pavia, Italy
    Clin Ther 25:2006-21. 2003
    ....
  31. ncbi Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Hypertens Res 29:849-56. 2006
    ..These observed metabolic effects of different angiotensin type 1 receptor blockers could be relevant when choosing a therapy to correct metabolic derangement of patients affected by metabolic syndrome and diabetes...
  32. ncbi Comparison of orlistat treatment and placebo in obese type 2 diabetic patients
    Giuseppe Derosa
    University of Pavia, Department of Internal Medicine and Therapeutics, 27100 Pavia, Italy
    Expert Opin Pharmacother 11:1971-82. 2010
    ..To evaluate the effects of 1-year treatment with orlistat compared with placebo on different inflammatory parameters in type 2 obese diabetic patients...
  33. ncbi Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy
    Endothelium 14:45-51. 2007
    ..MMP-9, TIMP-1, and TIMP-2 plasma levels were increased in diabetic patients with ACSs, which may reflect abnormal extracellular matrix metabolism in diabetes during acute event...
  34. ncbi Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy
    Intern Med 48:265-71. 2009
    ..We aimed to comparatively test the efficacy and tolerability of pioglitazone and sibutramine in metformin-intolerant obese type 2 diabetic patients treated with sibutramine...
  35. ncbi Candesartan effect on inflammation in hypertension
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy
    Hypertens Res 33:209-13. 2010
    ..We observed that candesartan treatment attenuated the inflammatory answer in both groups of patients, even if more efficiently in nondiabetic ones...
  36. ncbi Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial
    Giuseppe Derosa
    Department o f Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy
    Clin Ther 29:602-10. 2007
    ..The autonomic nervous system plays an important part in the homeostasis of blood pressure (BP), and sympathetic overactivity may contribute to metabolic conditions such as glycemic intolerance or insulin resistance...
  37. ncbi Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Clinica Medica II, IRCCS Policlinico S Matteo, University of Pavia, Piazzale Golgi 19, 27100, Pavia, Italy
    Eur J Clin Pharmacol 62:817-22. 2006
    ..The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients...
  38. ncbi Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Hypertens Res 33:790-5. 2010
    ..Both treatments resulted in a similar reduction in Hs-CRP. Although both therapies resulted in similar reductions in blood pressure, candesartan therapy was more effective than olmesartan therapy in improving insulin sensitivity...
  39. ncbi Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy
    Hypertens Res 30:387-94. 2007
    ....
  40. ncbi Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, 19 27100 Pavia, Italy
    Metabolism 57:1552-7. 2008
    ..Sibutramine appears to be a tolerable and efficacious drug when added to pioglitazone for the global management of obese diabetic patients...
  41. ncbi Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro Ipertensione e Fisiopatologia Cardiovascolare, University of Pavia, Pavia, Italy
    Hypertens Res 34:1321-6. 2011
    ..This suggests that the different effect of angiotensin-converting enzyme inhibitors and Ang II blockers on Ang II production has a role in their different influence on fibrinolysis...
  42. ncbi Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients
    Giuseppe Derosa
    Fondazione IRCCS Policlinico S Matteo, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, P le C Golgi, 2 27100 Pavia, Italy
    Fundam Clin Pharmacol 25:642-51. 2011
    ....
  43. ncbi Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, P le C Golgi 2, 27100 Pavia, Italy
    Biomed Pharmacother 63:723-33. 2009
    ..Pioglitazone improves glucose metabolism and insulin-resistance compared to acarbose in type 2 diabetic patients already treated with metformin and sulphonilureas...
  44. ncbi Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, 2 27100 Pavia, Italy
    Metabolism 58:1059-66. 2009
    ..Pioglitazone-metformin-based therapeutic control is associated with the most quantitatively relevant improvement in insulin resistance-related parameters, whereas the sulfonylurea-metformin-including protocol has less relevant effects...
  45. ncbi Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Clin Invest Med 32:E124-32. 2009
    ..To evaluate the distribution of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and their specific inhibitors in a sample of patients affected by mild dyslipidemia but not yet treated with antihyperlipidemic drugs...
  46. ncbi Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Clinica Medica II Fondazione IRCCS Policlinico S Matteo, University of Pavia, Italy
    Hypertens Res 31:43-50. 2008
    ..However, manidipine/delapril offered some advantages in terms of the less-pronounced BP orthostatic changes and absence of metabolic adverse effects...
  47. ncbi Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Diabetes Technol Ther 14:475-84. 2012
    ..This study evaluated the effect of vildagliptin + metformin on glycemic control and β-cell function in type 2 diabetes patients...
  48. ncbi Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro Ipertensione e Fisiopatologia Cardiovascolare, University of Pavia, Pavia, Italy
    Eur J Gastroenterol Hepatol 24:164-71. 2012
    ....
  49. ncbi Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy
    Hypertens Res 34:145-51. 2011
    ....
  50. ncbi Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Microvasc Res 80:110-5. 2010
    ..We observed that nitrites/nitrates and ADP significantly decreased and MMP-2 and MMP-9 significantly increased after a standardized OFL. Other studies need to confirm the direct acute effects of post-prandial lipemia on vascular damage...
  51. ncbi Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Metabolism 59:887-95. 2010
    ....
  52. ncbi Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Clinica Medica II IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy
    Am J Hypertens 20:417-22. 2007
    ..Aim of this study was to evaluate the effect of the telmisartan-amlodipine combination at different doses on urinary albumin excretion rate (UAER) in hypertensive diabetic patients with microalbuminuria...
  53. ncbi Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Arch Med Res 39:412-9. 2008
    ....
  54. ncbi Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients
    Roberto Fogari
    Clinica Medica II, Centro Ipertensione e Fisiopatologia Cardiovascolare, Department of Internal Medicine and Therapeutics, University of Pavia, Italy
    Adv Ther 27:48-55. 2010
    ..The objective of this study was to compare the effect on ankle edema of adding valsartan (V) or olmesartan (O) to amlodipine (A) in the treatment of hypertension...
  55. ncbi Oral fat load effects on inflammation and endothelial stress markers in healthy subjects
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS, Policlinico San Matteo, P C Golgi 2, 27100 Pavia, Italy
    Heart Vessels 24:204-10. 2009
    ..05 vs 0), and +28.57% at 12 h. We observed that the OFL induces a complex and massive systemic inflammatory response that includes IL-6, TNF-alpha, hsCRP, and cell adhesion molecules, even before Tg significantly rises...
  56. ncbi Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI)
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Endocr J 56:571-8. 2009
    ..CSII therapy allows a faster and better achievement of the therapeutic target and also gives an improvement of the lipid profile...
  57. ncbi Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro per l Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia, Pavia, Italy
    Am J Hypertens 21:1034-9. 2008
    ..This study compared the effect of antihypertensive treatment with valsartan or ramipril on atrial fibrillation (AF) recurrence, on P-wave dispersion, (PWD) and on serum procollagen type I carboxy terminal peptide (PIP)...
  58. ncbi Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, P le C Golgi, 2 27100 Pavia, Italy
    J Pharm Pharm Sci 13:378-90. 2010
    ..Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients...
  59. ncbi Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Clin Drug Investig 26:529-39. 2006
    ..The aim of this study was to evaluate if the expected improvement in glucose and lipid metabolism obtainable with doxazosin is or is not synergistic with standard antihyperglycaemic treatment using the alpha-glucosidase inhibitor acarbose...
  60. ncbi Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Eur J Pharmacol 651:240-50. 2011
    ..Acarbose was more effective than acarbose in reducing the post-OFL peaks of the various parameters included the inflammatory markers, after 7months of therapy...
  61. ncbi Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro per l Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia, Pavia, Italy
    J Cardiovasc Pharmacol 51:217-22. 2008
    ..Despite similar BP reduction, valsartan/amlodipine combination was more effective in patients treated with amiodarone or propafenone than atenolol/amlodipine in preventing new episodes of AF in hypertensive diabetic patients...
  62. ncbi Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Curr Med Res Opin 25:607-15. 2009
    ..The second endpoint was to evaluate which of these two treatment is more efficacious in the global management of glucose homeostasis in the enrolled patients...
  63. ncbi Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Endocr J 57:777-86. 2010
    ....
  64. ncbi Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, P le C Golgi, 2 27100 Pavia, Italy
    Microvasc Res 79:144-9. 2010
    ..MMP-9 levels were higher in D group than in H group during OGTT. Postprandial glycemia induces an acute increase in biomarkers of vascular remodelling...
  65. ncbi Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study
    Roberto Fogari
    Clinica Medica II, University of Pavia, Centro Ipertensione e Fisiopatologia Cardiovascolare, Department of Internal Medicine and Therapeutics, Pavia, Italy
    Expert Opin Pharmacother 12:1351-8. 2011
    ..The aim of this study was to assess the effect of aliskiren and amlopidine on ankle-foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP)...
  66. ncbi Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Clinica Medica II IRCCS Policlinico S.Matteo, University of Pavia, Pavia, Italy
    Am J Hypertens 17:823-7. 2004
    ....
  67. ncbi Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Clinica Medica II, Centro Ipertensione e Fisiopatologia Cardiovascolare, University of Pavia, Pavia, Italy
    Hypertens Res 34:509-15. 2011
    ....
  68. ncbi Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro Ipertensione e Fisiopatologia Cardiovascolare, University of Pavia, Pavia, Italy
    Hypertens Res 33:236-42. 2010
    ..Half of the patients who had normalized BMI also had normalized BP, which could indicate that these patients essentially did not have a form of hypertension but that these effects were instead secondary to being overweight...
  69. ncbi Efficacy and safety of two treatment combinations of hypertension in very elderly patients
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro per l Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia, Piazzale Golgi 19, I 27100 Pavia, Italy
    Arch Gerontol Geriatr 48:401-5. 2009
    ..However, valsartan/amlodipine offered some advantages in terms of less pronounced BP orthostatic changes and absence of metabolic adverse effects...
  70. ncbi Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    J Clin Pharm Ther 32:261-8. 2007
    ..The aim of our study was to investigate the metabolic effects of telmisartan and irbesartan in diabetic subjects treated with rosiglitazone...
  71. ncbi Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    J Clin Pharm Ther 31:375-83. 2006
    ....
  72. ncbi Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    J Clin Pharm Ther 34:13-23. 2009
    ..The aim of the present study was to compare the effects of nateglinide plus metformin with glibenclamide plus metformin on glucose and lipid metabolism, and haemodynamic parameters in patients with type 2 diabetes mellitus...
  73. ncbi Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy
    Expert Rev Cardiovasc Ther 8:835-43. 2010
    ..For these reasons, the combination of amlodipine plus atorvastatin could be the treatment of choice in hypertensive and hypercholesterolemic patients...
  74. ncbi Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, IRCCS Policlinico S Matteo, University of Pavia, Italy
    Am J Hypertens 15:316-20. 2002
    ..Different effects of the two drugs on the bradykinin system might also be implicated...
  75. ncbi Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Italy
    Intern Med 46:1837-46. 2007
    ..To evaluate the effect on coagulation and fibrinolysis parameters and on non-conventional cardiovascular risk factors of metformin plus nateglinide or glibenclamide in naïve type 2 diabetes patients...
  76. ncbi Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro per l Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia, Pavia
    J Renin Angiotensin Aldosterone Syst 8:139-44. 2007
    ..Tolerance is an important clinical consideration in the chronic treatment of an asymptomatic disease...
  77. ncbi Exenatide versus glibenclamide in patients with diabetes
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Italy
    Diabetes Technol Ther 12:233-40. 2010
    ..The aim of our study was to evaluate the effects of exenatide compared to glibenclamide on body weight, glycemic control, beta-cell function, insulin resistance, and inflammatory state in patients with diabetes...
  78. ncbi Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Horm Metab Res 42:663-9. 2010
    ..Pioglitazone plus vildagliptin were found to be more effective in preserving beta-cell function, and in reducing insulin resistance, and inflammatory state parameters...
  79. ncbi Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro Ipertensione e Fisiopatologia Cardiovascolare, University of Pavia, Pavia, Italy
    Clin Exp Hypertens 32:245-50. 2010
    ..3%, ns). These results suggest that initial therapy with a V/A combination approach may be more quickly effective than a conventional sequential monotherapy approach in achieving target BP in hypertensive patients with metabolic syndrome...
  80. ncbi Effects of thiazolidinediones and sulfonylureas in patients with diabetes
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy
    Diabetes Technol Ther 12:491-501. 2010
    ..We also evaluated the effects of these two drugs on beta-cell function, insulin resistance, and inflammatory markers, also recording the frequency of adverse events such as edema and heart failure...
  81. ncbi Irbesartan and hydrochlorothiazide association in the treatment of hypertension
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Curr Vasc Pharmacol 7:120-36. 2009
    ..Ongoing trials about irbesartan and its combination with diuretics may provide necessary data to interpret the value of this association among others...
  82. ncbi Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, IRCCS Policlinico S Matteo, Pavia, Italy
    Intern Med J 37:79-86. 2007
    ....
  83. ncbi Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, IRCCS Policlinico S Matteo, P le C Golgi 2, 27100 Pavia, Italy
    Diabetes Res Clin Pract 60:161-9. 2003
    ..To compare glycaemic control and cardiovascular risk profile in patients with type 2 diabetes following 12 months' treatment with either repaglinide or metformin...
  84. ncbi Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Clinica Medica IRCCS Policlinico S Matteo, University of Pavia, Piazzale Golgi 2, 27100 Pavia, Italy
    Eur J Clin Pharmacol 58:177-80. 2002
    ..To compare the effects of valsartan and atenolol on sexual activity and plasma testosterone in newly diagnosed, previously untreated, essential hypertensive male subjects...
  85. ncbi Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy
    Hypertens Res 28:209-14. 2005
    ..These results suggest that in hypertensive obese subjects, treatment with valsartan might offer an advantage over treatment with felodipine, since valsartan may help to improve obesity-related disorders in addition to lowering BP...
  86. ncbi Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients
    Roberto Fogari
    Department of Internal Medicine and Therapeutics, Centro per l Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia, Italy
    Intern Med 47:1851-7. 2008
    ..The aim of the study was to evaluate the effect of valsartan/amlodipine combination on insulin sensitivity in overweight-obese hypertensive patients...
  87. ncbi Matrix metalloproteinase-2 and -9 levels in obese patients
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Endothelium 15:219-24. 2008
    ..MMP-2 and MMP-9 levels were significantly higher in obese group (p< .0001). Plasma levels of MMP-2 and MMP-9 are increased in obese patients which may reflect abnormal ECM metabolism...
  88. ncbi Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus
    A Mugellini
    Department of Internal Medicine and Therapeutics, Clinica Medica II, IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy
    J Hum Hypertens 18:687-91. 2004
    ....
  89. ncbi Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, 2 27100 Pavia, Italy
    Curr Med Res Opin 25:1973-83. 2009
    ..We evaluated lipids, glycaemic, haemostatic, and inflammatory variables at baseline, and after 6 and 12 months...
  90. ncbi Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients
    R Fogari
    Dipartimento di Medicina Interna, Clinica Medica II, IRCCS Policlinico S Matteo, Universita di Pavia, Pavia, Italy
    J Hum Hypertens 21:220-4. 2007
    ..These results suggest that angiotensin receptor blockers partially counteract the microcirculatory changes responsible for calcium channel blockers induced oedema formation...
  91. ncbi Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, P le C Golgi 2, 27100 Pavia, Italy
    Horm Metab Res 42:8-13. 2010
    ..Type 2 diabetics experienced, however, a more significant increase in TNF-alpha, and sE-selectin...
  92. ncbi Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, Piazzale C Golgi 2, 27100 Pavia, Italy
    Diabetes Metab 33:129-34. 2007
    ..To test this hypothesis, we measured the plasma levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 in type 2 diabetic patients and in healthy subjects...
  93. ncbi Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy
    R Fogari
    Department of Internal Medicine, Clinica Medica II, IRCCS Policlinica San Matteo, University of Pavia, Pavia, Italy
    Adv Ther 23:680-95. 2006
    ..05). These findings suggest that the addition of HCTZ 12.5 mg to valsartan 160 mg monotherapy produces a greater BP reduction than the addition of the same dose of HCTZ to olmesartan 20 mg monotherapy...
  94. ncbi Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients
    R Fogari
    Department of Internal Medicine and Therapeutics, Centro Ipertensione e Fisiopatologia Cardiovascolare, University of Pavia, 27100 Pavia, Italy
    Horm Metab Res 41:893-8. 2009
    ....
  95. ncbi Effects of a restricted sleep regimen on ambulatory blood pressure monitoring in normotensive subjects
    P Lusardi
    Department of Internal Medicine and Therapeutics, University of Pavia, Italy
    Am J Hypertens 9:503-5. 1996
    ....
  96. ncbi Influence of losartan and atenolol on memory function in very elderly hypertensive patients
    R Fogari
    Department of Internal Medicine and Therapeutics, Clinica Medica II, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    J Hum Hypertens 17:781-5. 2003
    ..05) for both memory tests. These data suggest that in very elderly hypertensive patients, chronic AT1 receptor blockade by losartan could improve cognitive function, in particular immediate and delayed memory...
  97. ncbi IFN-gamma low production capacity in type 1 diabetes mellitus patients at onset of disease
    M A Avanzini
    Research Laboratories for Pediatric Oncohematology and Immunology, IRCCS Policlinico S Matteo, Pavia, Italy
    Exp Clin Endocrinol Diabetes 113:313-7. 2005
    ....
  98. ncbi Prospects for the development of novel anti-hyperlipidemic drugs
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Italy
    Curr Opin Investig Drugs 7:826-33. 2006
    ....
  99. ncbi Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease
    Arrigo F G Cicero
    GC Descovich Atherosclerosis and Metabolic Disease Research Unit, D Campanacci Clinical Medicine and Applied Biotechnology Department, Alma Mater Studiorum University of Bologna, Bologna, Italy
    Endothelium 14:193-8. 2007
    ..However, the superposition of MS on FCH further increases the plasma level of these parameters. The prognostic value of this observation has to be evaluated...
  100. ncbi Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes
    Giuseppe Derosa
    Diabetes Care 27:273-4. 2004
  101. ncbi Different effect of psyllium and guar dietary supplementation on blood pressure control in hypertensive overweight patients: a six-month, randomized clinical trial
    Arrigo F G Cicero
    GC Descovich Atherosclerosis Research Centre, D Campanacci Clinical Medicine and Applied Biotechnology Dept, University of Bologna, Italy
    Clin Exp Hypertens 29:383-94. 2007
    ..In our study, six-month supplementation with psyllium fiber, but not with guar fiber nor standard diet, appears to significantly reduce both SBP and DBP in hypertensive overweight subjects...